GE Healthcare Technologies (GEHC) expects Flyrcado imaging agent sales of $500 million by 2028, but a slower-than-expected launch has weakened buy-side confidence in the product, UBS Securities said.

The adoption of the Flyrcado tracer, used to diagnose coronary artery disease, is being limited by radiopharmacy investment requirements, hospital switching costs and uncertainty over future reimbursement, analysts wrote in a Wednesday research report.

The investment firm said the shares are reasonably priced but expects the challenges around Flyrcado to slow adoption and leave its earnings estimates below consensus from 2027 onward.

UBS reiterated its neutral rating on the stock and cut its price target to $67 per share from $69.

Shares of GE Healthcare were up 1.5% in Thursday afternoon trading.

Price: 64.17, Change: +0.97, Percent Change: +1.53